Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.38 |
| ▸ | THRA | P10827 | 10/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739731 | 0.83 | THRA (0.58) | THRBTHRA | |
| SCHEMBL7200954 | 0.79 | ALDH1A1 (0.43) | — | |
| SCHEMBL14489130 | 0.75 | THRB (0.62) | THRBTHRA | |
| SCHEMBL7568596 | 0.75 | GAA (0.50) | THRBTHRA | |
| SCHEMBL7042666 | 0.74 | THRB (0.55) | THRBTHRA | |
| SCHEMBL4961754 | 0.73 | GAA (0.41) | THRBTHRA | |
| SCHEMBL26412547 | 0.73 | MAPT (0.40) | THRBTHRA | |
| SCHEMBL7040382 | 0.73 | THRB (0.53) | THRBTHRA | |
| SCHEMBL7613144 | 0.73 | THRA (0.39) | THRBTHRAF10 | |
| SCHEMBL7518037 | 0.70 | THRA (0.56) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790978-B2 | 4-HYDROXY-3-ARYLSULFONYL, 3-AMINOSULFONYL OR 3-AMINOCARBONYL-PHENOXYANILINOCARBONYL-OPTIONAL ALKYLENE-CARBOXYLIC ACID OR CARBONYL-5-TETRAZOLES | NOVARTIS AG (CH) | 2004-09-14 | — | — | US | disclosed |
| US-6689896-B2 | AMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2004-02-10 | — | — | US | disclosed |
| US-6599942-B1 | Method of lowering LDL cholesterol and Lipoprotein a levels in mammals using such compounds | NOVARTIS AG (CH) | 2003-07-29 | — | — | US | disclosed |
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045751-A1 | Thyromimetic organic compounds | TPO, THRA, LPO | THRB 7/4885THRA 2/4885F10 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.